NEW YORK (GenomeWeb News) – Swiss proteomics firm Biognosys said this week that it has secured $1.0 million in funding in the form of a convertible loan.

The company, which specializes in targeted proteomics and mass spec-based biomarker discovery, said it will use the money to expand its commercial operations and product development.

Biognosys was spun out of Ruedi Aebersold's laboratory in 2008 at the Swiss Federal Institute of Technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.